Trexquant Investment’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.16M | Buy |
389,467
+224,450
| +136% | +$5.05M | 0.06% | 452 |
|
|
2025
Q4 | $3.8M | Buy |
165,017
+9,629
| +6% | +$317K | 0.03% | 716 |
|
|
2025
Q3 | $4.67M | Sell |
155,388
-79,524
| -34% | -$2.38M | 0.05% | 574 |
|
|
2025
Q2 | $8.54M | Sell |
234,912
-33,754
| -13% | -$1.22M | 0.1% | 309 |
|
|
2025
Q1 | $9.73M | Buy |
268,666
+112,010
| +72% | +$4.66M | 0.11% | 260 |
|
|
2024
Q4 | $6.59M | Sell |
156,656
-10,611
| -6% | -$526K | 0.08% | 416 |
|
|
2024
Q3 | $9.29M | Buy |
167,267
+148,502
| +791% | +$7.56M | 0.12% | 258 |
|
|
2024
Q2 | $771K | Sell |
18,765
-44,398
| -70% | -$1.9M | 0.01% | 1092 |
|
|
2024
Q1 | $2.95M | Buy |
63,163
+9,663
| +18% | +$456K | 0.06% | 505 |
|
|
2023
Q4 | $2.56M | Buy |
53,500
+23,952
| +81% | +$929K | 0.06% | 471 |
|
|
2023
Q3 | $1.05M | Buy |
29,548
+668
| +2% | +$26.5K | 0.03% | 733 |
|
|
2023
Q2 | $1.33M | Buy |
28,880
+4,707
| +19% | +$218K | 0.03% | 660 |
|
|
2023
Q1 | $969K | Sell |
24,173
-19,834
| -45% | -$851K | 0.03% | 743 |
|
|
2022
Q4 | $2.04M | Buy |
44,007
+19,703
| +81% | +$775K | 0.06% | 406 |
|
|
2022
Q3 | $1.01M | Buy |
24,304
+2,316
| +11% | +$119K | 0.04% | 531 |
|
|
2022
Q2 | $1.31M | Buy |
21,988
+9,853
| +81% | +$606K | 0.06% | 406 |
|
|
2022
Q1 | $881K | Buy |
+12,135
| New | +$844K | 0.04% | 522 |
|
|
2021
Q3 | – | Sell |
-9,175
| Closed | -$875K | – | 1420 |
|
|
2021
Q2 | $875K | Buy |
+9,175
| New | +$956K | 0.07% | 337 |
|
|
2020
Q4 | – | Sell |
-5,120
| Closed | -$421K | – | 1410 |
|
|
2020
Q3 | $421K | Sell |
5,120
-6,279
| -55% | -$520K | 0.03% | 771 |
|
|
2020
Q2 | $892K | Buy |
+11,399
| New | +$754K | 0.06% | 435 |
|
|
2019
Q3 | – | Sell |
-6,062
| Closed | -$385K | – | 1072 |
|
|
2019
Q2 | $385K | Buy |
+6,062
| New | +$386K | 0.03% | 536 |
|
|
2019
Q1 | – | Sell |
-11,852
| Closed | -$515K | – | 1253 |
|
|
2018
Q4 | $515K | Buy |
+11,852
| New | +$648K | 0.03% | 603 |
|
|
2018
Q3 | – | Sell |
-13,645
| Closed | -$1.05M | – | 1149 |
|
|
2018
Q2 | $1.05M | Buy |
+13,645
| New | +$881K | 0.07% | 364 |
|
|
2017
Q1 | – | Sell |
-3,600
| Closed | -$253K | – | 1281 |
|
|
2016
Q4 | $253K | Sell |
3,600
-3,200
| -47% | -$227K | 0.04% | 717 |
|
|
2016
Q3 | $482K | Sell |
6,800
-27,465
| -80% | -$1.75M | 0.11% | 323 |
|
|
2016
Q2 | $1.68M | Buy |
34,265
+30,168
| +736% | +$1.95M | 0.22% | 125 |
|
|
2016
Q1 | $259K | Sell |
4,097
-4,903
| -54% | -$321K | 0.03% | 776 |
|
|
2015
Q4 | $1.01M | Buy |
+9,000
| New | +$900K | 0.09% | 388 |
|
|
2015
Q1 | – | Sell |
-15,400
| Closed | -$675K | – | 1149 |
|
|
2014
Q4 | $675K | Buy |
+15,400
| New | +$706K | 0.12% | 322 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Trexquant Investment's RARE Position: Q1 2026 in Review
Trexquant Investment increased its Ultragenyx Pharmaceutical (RARE) stake by 136% in Q1 2026, buying an estimated $5.05M and bringing the position to 389,467 shares worth $8.16M. The position accounts for 0.06% of the portfolio, ranked #452.
Trexquant Investment first reported a position in RARE in Q4 2014 and has held it in 29 quarters since. The position peaked at $9.73M in Q1 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Trexquant Investment held 389,467 shares of Ultragenyx Pharmaceutical worth $8.16M as of Q1 2026.
- Trexquant Investment bought 224,450 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $5.05M.
- Ultragenyx Pharmaceutical made up 0.06% of Trexquant Investment's portfolio in Q1 2026, its #452 holding.
- Trexquant Investment first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 29 quarters since.
- Trexquant Investment's Ultragenyx Pharmaceutical position peaked at $9.73M in Q1 2025.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.